

Delayed mortality among solid organ transplant recipients hospitalized for COVID-19

Madeleine R. Heldman MD^{1,2}, Olivia S. Kates MD MA³, Kassem Safa MD⁴, Camille N. Kotton MD,⁴ Ashrit Multani MD⁵, Sarah J. Georgia CNP⁴, Julie M. Steinbrink MD⁶, Barbara D. Alexander MD⁶, Emily A. Blumberg MD⁷, Brandy Haydel CCRC⁸, Vagish Hemmige MD⁹, Marion Hemmersbach-Miller MD PhD¹⁰, Ricardo M. La Hoz MD¹¹, Lisset Moni MBA¹², Yesabeli Condor MD¹², Sandra Flores¹², Carlos G. Munoz MD¹², Juan Guitierrez¹², Esther I. Diaz¹², Daniela Diaz¹², Rodrigo Vianna MD PhD¹², Giselle Guerra MD¹², Matthias Loebe MD PhD¹², Julie M. Yabu MD MTM⁵, Kailey Hughes Kramer MPH¹³, Sajal D. Tanna MD MPH¹⁴, Michael G. Ison MD MS¹⁴, Robert M. Rakita¹ MD¹, Maricar Malinis MD¹⁵, Marwan M. Azar MD¹⁵, Margaret E. McCort MD MS⁸, Pooja P. Singh, MD¹⁶, Arzu Velioglu MD¹⁷, Sapna A. Mehta¹⁸, David van Duin MD PhD¹⁹, Jason D. Goldman MD MPH^{1,20}, Erika D. Lease MD²¹, Anna Wald MD^{1,2,22,23}, Ajit P. Limaye MD^{1,23*} and Cynthia E. Fisher MD MPH^{1*} On behalf of the UW Covid-19 SOT Study Team

* Cynthia E. Fisher and Ajit P. Limaye contributed equally to this work

1, Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, WA, USA

2, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA

3, Division of Infectious Diseases, Johns Hopkins University, Baltimore, MD, USA

4, Massachusetts General Hospital, Boston, MA, USA

5, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA

6, Division of Infectious Diseases, Duke University, Durham, NC, USA

© The Author(s) 2022. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

7, Division of Infectious Diseases, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA

8, Recanati/Miller Transplantation Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA

9, Division of Infectious Disease, Albert Einstein College of Medicine / Montefiore Medical Center, Bronx, NY, USA

10, Section of Infectious Diseases, Baylor College of Medicine, Houston, TX, USA

11, Division of Infectious Diseases and Geographic Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA

12, University of Miami/Jackson Memorial Hospital, Miami, FL, USA

13, Transplant Infectious Diseases, University of Pittsburgh, Pittsburgh, PA, USA

14, Division of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, IL, USA

15, Section of Infectious Diseases, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA

16, Division of Nephrology, University of New Mexico, Albuquerque, NM, USA

17, Marmara University, School of Medicine, Department of Internal Medicine, Division of Nephrology, Istanbul, Turkey

18, NYU Langone Transplant Institute, New York, NY, USA

19, Division of Infectious Diseases, University of North Carolina, Chapel Hill, NC, USA

20, Swedish Medical Center, Seattle, WA, USA

21, Division of Pulmonology, Critical Care, and Sleep Medicine, Department of Medicine, University of Washington, Seattle, WA, USA

22, Department of Epidemiology, University of Washington, Seattle, WA, USA

23, Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA

Correspondence:

Madeleine R. Heldman, MD

University of Washington Medical Center

1959 NE Pacific St. Box 356423

Seattle, WA 98195

Email: mrh157@uw.edu

Summary: A significant proportion (>20%) of deaths among solid organ transplant recipients hospitalized for COVID-19 occur beyond the typical one-month follow-up period used to calculate mortality in traditional studies. Comprehensive assessments of mortality in COVID-19 should consider extended follow-up durations.

Accepted Manuscript

Abstract

Introduction: Most studies of solid organ transplant (SOT) recipients with COVID-19 focus on outcomes within one month of illness onset. Delayed mortality in SOT recipients hospitalized for COVID-19 has not been fully examined.

Methods: We used data from a multicenter registry to calculate mortality by 90 days following initial SARS-CoV-2 detection in SOT recipients hospitalized for COVID-19 and developed multivariable Cox proportional-hazards models to compare risk factors for death by days 28 and 90.

Results: Vital status at day 90 was available for 936 of 1117 (84%) SOT recipients hospitalized for COVID-19: 190 of 936 (20%) died by 28 days and an additional 56 of 246 deaths (23%) occurred between days 29 and 90. Factors associated with mortality by day 90 included: age > 65 years [aHR 1.8 (1.3-2.4), $p < 0.001$], lung transplant (vs. non-lung transplant) [aHR 1.5 (1.0-2.3), $p = 0.05$], heart failure [aHR 1.9 (1.2-2.9), $p = 0.006$], chronic lung disease [aHR 2.3 (1.5-3.6), $p < 0.001$] and body mass index ≥ 30 kg/m² [aHR 1.5 (1.1-2.0), $p = 0.02$]. These associations were similar for mortality by day 28. Compared to diagnosis during early 2020 (March 1-June 19, 2020), diagnosis during late 2020 (June 20-December 31, 2020) was associated with lower mortality by day 28 [aHR 0.7 (0.5-1.0), $p = 0.04$] but not by day 90 [aHR 0.9 (0.7-1.3), $p = 0.61$].

Conclusions: In SOT recipients hospitalized for COVID-19, >20% of deaths occurred between 28 and 90 days following SARS-CoV-2 diagnosis. Future investigations should consider extending follow-up duration to 90 days for more complete mortality assessment.

Introduction

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been a global pandemic since March 2020. Many observational studies and randomized clinical trials measuring COVID-19 mortality have used ≤ 1 month follow-up periods to assess mortality [1-7]. However, a substantial number of patients remain alive but critically ill with continued risk for imminent death beyond 28 days after diagnosis, and some patients who appear to have recovered from COVID-19 experience worsening of symptoms later in their disease course [1]. In the general population, 15-25% of all deaths in patients hospitalized for COVID-19 during the first 90 days of illness occur after day 30 [8-11]. Thus, mortality measured at 90 days, rather than 28 or 30 days, may provide a more comprehensive understanding of COVID-19 associated mortality.

Solid organ transplant (SOT) recipients are at risk for severe COVID-19 [4, 12, 13]. While short-term mortality is well characterized in SOT recipients with COVID-19, few investigations have focused on outcomes beyond one month. Capturing delayed mortality is particularly relevant in SOT recipients, as experience with the solid organ transplant process' emphasis on survival may lead to greater pursuit of life-prolonging interventions during critical illness [14]. SOT recipients receiving chronic immunosuppressive therapies and/or certain COVID-19 therapies, such as high-dose corticosteroids, may be at higher risk for secondary opportunistic infections and associated late mortality [15]. We previously described outcomes in the first 28 days following SARS-CoV-2 diagnosis among SOT recipients enrolled in a multicenter registry [12, 16-18]. We used additional data from this registry to calculate mortality by 90 days among SOT recipients hospitalized for COVID-19 and to determine whether risk factors for death by 28 days are also predictive of death by 90 days.

Methods

Study Design and Participants

We performed a multicenter observational cohort study of SOT recipients with laboratory confirmed SARS-CoV-2 infection who were hospitalized for COVID-19 within 28 days of diagnosis and for whom vital status at day 28 was available, as previously described [12, 16, 17]. Patients were excluded if they were hospitalized for another indication prior to or concurrent with their first positive SARS-CoV-2 test. Patients who survived to day 28 were either followed through day 90 (last live encounter \geq 90 days from diagnosis or documented day of death between days 29-90) or considered lost to follow-up. This study was approved by the institutional review board (IRB) at the University of Washington with a waiver of informed consent (STUDY00009698). The University of Washington IRB issued a “no human subjects research” designation for local sites contributing de-identified patient data. Individual sites sought local IRB approval as needed.

Data Collection

We invited transplant providers to submit de-identified data regarding SOT recipients with SARS-CoV-2 infections to REDCap (Research Electronic Data Capture), a secure, web-based data capture software program, housed at the University of Washington [19]. Contributors were recruited from discussion boards of the American Society of Transplantation and International Society for Heart and Lung Transplantation and asked to complete three electronic surveys: 1) an initial form at time of first positive SARS-CoV-2 test which included medical history and details regarding clinical presentation, 2) a 28 day follow up form with information on the clinical course during the first 28 days following first positive SARS-CoV-2 test and 3) a 90 day follow up form with information on patients' vital status at 90 days. On each follow-up form, the contributor was asked to report the number of days between first positive SARS-CoV-2 test (day 0) and most recent healthcare contact. For patients who died, contributors were asked to report the number of days between first positive SARS-CoV-2 test and death. The registry was open to new cases diagnosed between March 1 and

December 31, 2020 and remained open to follow-up reports through April 19, 2021. Completed case report forms were reviewed by the study team and inconsistencies were adjudicated via communication with the contributor whenever possible.

Statistical Analysis

Demographic and baseline characteristics were assessed as counts and percentages for categorical values and as a median (interquartile range) for continuous variables. We calculated the mortality by 90 days among all patients for whom vital status at day 90 was available. To account for the potential impact of patients who were lost to follow-up after day 28 and whose vital status at 90 days was unknown, we performed a sensitivity analysis to calculate the range of possible mortality values for the entire cohort of SOT recipients hospitalized for COVID-19. The minimum value of this range assumed that 0% of the subjects lost to follow-up died before day 90, and the maximum value of this range assumed that 100% of the subjects lost to follow-up died before day 90.

We used univariable and multivariable Cox proportional-hazards models to assess associations between selected covariates and death by 28 and 90 days following first positive SARS-CoV-2 test. Patients were censored at last live encounter if lost to follow-up before 90 days. Specific covariates were selected based on hypotheses and prior publications indicating associations with worse outcomes in SOT recipients hospitalized for COVID-19 [12, 16, 17]. Covariates with a p-value <0.05 in univariable analysis for 28-day mortality were included in multivariable models. Time period of diagnosis was classified as a dichotomous variable—early 2020 (March 1-June 19, 2020) and late 2020 (June 20-December 31, 2020)—because the time cutoff in June 2020 closely coincided with a paradigm shift in the care of patients with COVID-19 in response to evidence supporting use of corticosteroids for patients requiring supplemental oxygen and the emergency use authorization of remdesivir in the United States [17, 20-22]. Most data were complete;

multiple imputations by chained equations was used to account for missing covariates in multivariable analyses [23]. Stata version 16.1 (StataCorp, College Station, TX) and R version 4.0.2 were used to perform the statistical analyses. Figures were created using R version 4.0.2 and Excel (Microsoft, Redmond, WA).

Results

Study Population

Of 1702 SOT recipients with SARS-CoV-2 infections, 1141 (67%) were hospitalized for COVID-19 within 28 days after first positive SARS-CoV-2 test; 1117 of 1141 (98%) were followed through death or day 28 and therefore included in the analyses (**Figure S1**). Six hundred ninety-four (62%) were men and the median age was 59 years (IQR: 49-67 years). Three hundred sixty-eight (34%) had undergone SOT within 2 years of SARS-CoV-2 infection; 563 (50%) had diabetes mellitus, 69 (6%) had heart failure, and 74 (7%) had chronic lung disease. There were 693 (62%) kidney recipients, 147 (14%) liver recipients, 137 (12%) heart recipients and 127 (11%) lung recipients. First positive SARS-CoV-2 test occurred during early 2020 in 593 (53%) patients. Of patients with available lab and imaging results at presentation, lymphopenia was present in 325 (32%) and chest imaging was abnormal in 835 (82%), respectively. One hundred ninety (17%) were deceased and 927 (83%) were alive at day 28. Among 927 who survived to day 28, 746 (80%) were followed through death or day 90 while 181 (20%) were lost to follow-up. Overall, characteristics of patients followed through death or day 90 were similar to those lost to follow-up (**Table S1**, supplementary materials). Vital status at day 90 was available for 936 patients (190 who died within 28 days and 746 who survived beyond 28 days).

Calculated mortality in the first 90 days following first positive SARS-CoV-2 test

Among 936 hospitalized SOT recipients whose vital status at day 90 was confirmed, 246 (26.3%) died within the first 90 days following diagnosis. Fifty-six of 746 (7.5%) patients who survived to day 28 died by day 90. In a sensitivity analysis including the entire cohort of 1117 SOT recipients,

the minimum possible mortality by 90 days was 22% and the maximum possible mortality was 38% (Table 2). Figure 1 shows unadjusted survival curves during the first 90 days following first positive SARS-CoV-2 test in all 1117 hospitalized SOT recipients (Figure 1A), and stratified by organ (Figure 1B) and time period of diagnosis (Figure 1C).

Of all 246 deaths within the first 90 days, 56 (23%) occurred beyond day 28 (Figure 2). Deaths after day 28 were more likely to occur in men (45/164, 27%) than in women (10/81, 12%) and more likely to occur in patients diagnosed in late 2020 (32/87, 37%) than in patients diagnosed during early 2020 (17/132, 13%, Table S2, supplementary materials).

Risk factors for mortality within 90 days of first positive SARS-CoV-2 test

Older age, comorbidities (heart failure, chronic lung disease and BMI ≥ 30 kg/m²), lung transplant (vs. non-lung transplant), and factors associated with severe disease at presentation (lymphopenia and abnormal chest imaging) were associated with increased mortality by 28 days and 90 days in univariable (Table 3) and multivariable Cox proportional hazards models (Table 4). Compared to diagnosis in the early period of 2020, diagnosis in the late period of 2020 was associated with lower mortality at 28 days (aHR 0.7, 95% CI 0.5-1.0, p=0.04) but not at 90 days (aHR 0.9, 95% CI 0.7-1.3, p=0.61). Similarly, mTOR inhibitor use was associated with significantly lower mortality by 28 days (aHR 0.3, 95% CI 0.1-1.0, p=0.05) but the association was weaker by 90 days (aHR 0.5, 95% CI 0.2-1.1, p=0.07).

Discussion

This large, multicenter study with standardized 90-day follow-up identified the frequency of and risk factors for delayed mortality in SOT recipients hospitalized for COVID-19. Approximately 8% of patients who survived to day 28 following initial positive SARS-CoV-2 test died between days 29 and 90, and more than 20% of deaths within the first 90 days occurred beyond day 28. These data emphasize the importance of extended follow-up in measurements COVID-19 associated mortality.

Most large observational studies of SOT recipients with COVID-19 assessed mortality within 30 days of diagnosis, did not use a standardized follow-up period, or did not report median follow-up duration [4, 12, 13, 24]. Investigations with limited follow-up periods facilitated rapid reporting early in the pandemic, but mortality estimates based on short or variable follow-up periods are challenging to interpret. In the general population, 90-day mortality in patients hospitalized for COVID-19 ranges from 25-30%, with 15-25% of all deaths occurring after day 30 [8-11]. In a study of 1680 kidney transplant recipients (65% of whom were hospitalized), mortality at day 90 was 21%, and 22% of all deaths occurred more than 30 days after diagnosis [25]. Another investigation of 707 SOT recipients and 707 propensity-matched non-SOT controls hospitalized for COVID-19 followed patients for 60 days and found that 17% of all deaths occurred beyond day 30 in both SOT and non-SOT patients [26]. Likewise, in a randomized controlled trial of baricitinib in the general population, 16% of all deaths occurred between 28 – 60 days after randomization [27]. Findings from our study, which focused on recipients of any solid organ who required hospitalization for COVID-19, highlights the significant proportion of patients who die beyond the initial month of observation.

The relatively high proportion of deaths after day 28 in both SOT and non-SOT populations may reflect unique aspects of COVID-19. Compared to patients hospitalized with influenza, patients hospitalized with COVID-19 have significantly longer lengths of stay and are more likely to develop complications of prolonged illness such as catheter related infections, pressure ulcers, and venous thromboemboli [28, 29]. Thus, fatal and non-fatal sequelae of COVID-19 may manifest relatively late, and prolonged follow-up may be more important in COVID-19-focused studies compared to investigations of other infections.

Most comorbidities identified as risk factors for mortality during the first 28 days were also risk factors for death by 90 days. Diagnosis during late 2020 was associated with lower mortality by day 28, but not by day 90. Such temporal trends could suggest that advances in the care of COVID-19 only delay mortality by a matter of days to weeks, although changes in COVID-19 management

cannot be causally linked to lower 28-day mortality. Notably, loss to follow-up after day 28 was more common during early 2020 than late 2020, and failure to capture late deaths in patients diagnosed during the early period may have led to the apparent elevation in mortality in the late period.

Critically ill SOT recipients may be less likely to receive recommendations for comfort-focused treatment as a result of the transplant process' emphasis on recipient survival, potentially delaying mortality compared to non-SOT patients [14, 30-32]. Our findings, in conjunction with previous reports, suggest that the delayed mortality in patients hospitalized for COVID-19 is comparable in SOT and non-SOT populations [8-11, 25, 26]. The impact of transplant status on decisions regarding life sustaining treatments is most pronounced early after transplant [31]. Most patients in this study underwent transplant more than two years before SARS-CoV-2 diagnosis, which may have limited detection of any associations between transplant status and time to death.

The reduced mortality seen in SOT recipients taking mTOR inhibitors prior to SARS-CoV-2 infection is intriguing. Multiple potential advantageous mechanisms of mTOR inhibition in COVID-19 have been proposed, including direct inhibition of viral replication and mitigation of cytokine release [33]. However, these mechanisms are speculative and not necessarily indicative of clinical benefits. Observational data from this study's populations, among whom mTOR inhibitor use was sparse, need to be interpreted with caution.

This study's size, inclusion of both kidney and non-kidney SOT recipients from multiple centers, and standardized follow-up duration are important strengths of this investigation. However, we acknowledge several potential limitations. Twenty percent of patients who survived to day 28 were lost to follow-up prior to day 90. Because loss to follow-up beyond day 28 may preclude capture of later deaths (or documentation of prolonged survival), any major differences in loss to follow-up by covariate category pose a potential threat to the accuracy of reported associations. Importantly, prevalence of older age and comorbidities, the strongest predictors of death in all subgroups at both 28 and 90 days, were similar between patients lost to follow-up and those

followed through death or day 90. Thus, loss to follow-up was unlikely to have had major effects on the results of multivariable analyses. This study took place prior to the advent of SARS-CoV-2 vaccines, which dramatically reduce mortality from COVID-19 in SOT recipients and the general population [34-37]. Nonetheless, findings from this study remain relevant as serious infections despite vaccination may occur in SOT recipients, and emergence of SARS-CoV-2 variants that escape vaccine-induced immunity is an ongoing concern [38, 39]. We were unable to capture granular data on management strategies and indications for hospitalization among participating centers. Despite potential limitations of heterogeneity in COVID-19 management, the multicenter nature of the study provides a valuable summary of COVID-19 mortality in a broad range of clinical contexts. Additional restrictions to the study design, which was intended to rapidly collect data in a high-risk population during a worldwide pandemic, have been described elsewhere [12, 16, 17].

In this large multicenter study of SOT recipients hospitalized for COVID-19, a substantial proportion of deaths in the first 90 days following SARS-CoV-2 diagnosis occurred after the 28-day follow-up period that is frequently used when assessing mortality. Older age, comorbidities, and lung transplantation remained important predictors of both 28-day and 90-day mortality. Future investigations focusing on COVID-19 mortality should consider extending follow-up duration to 90 days for more accurate capture of mortality and associated risk factors.

Acknowledgements:

The following are the members of the UW COVID-19 SOT Study Team, without whom this work would not have been possible: Behdad D. Besharatian MD, Maria Crespo MD, Rade Tomic MD, Sameep Sehgal MD, Dana Weisshaar MD, Reda Girgis MD, Cameron Lawrence BS, Joanna Nelson MD, William Bennett MD, Jennifer Leandro, Afrah Sait MD, Amy Rumore PharmD, Patricia West PhD, Amy Jeng MD, Valida Bajrovic MD, Erin P Bilgili BS, Tracy Anderson-Haag, PharmD, BCPS, Abigail Nastase, Abbas Badami MD, Jesus Alvarez-Garcia MD, Lyndsey Bowman-Anger PharmD, Lovelyn Julien MPH, Carlos Ortiz-Bautista MD, Rachel Friedman-Morocco MD, Kiran Gajurel MD, Lizbeth Cahuayme-Zuniga MD, Mark Wakefield MD, Monica Fung MD, Nicole Theodoropoulos MD MS, Sally T Chuang MD, Srividya Bhandaram MD, Massimiliano Veroux MD PhD, Bhavna Chopra MD, Diana Florescu MD, Danielle Witteck, Daniela Diaz, Kathryn Ripley, NP-C, Kapil Saharia MD MPH, Sanjeev Akkina MD, Todd P. McCarty MD, Ally Webb PharmD, Akanksha Arya MD, Giridhar Vedula MD, Jose-Marie El-Amm MD, M. Katherine Dokus, Arun Narayanan MD, Priscila Cilene Leon Bueno de Camargo MD, Rosemary Ouseph MD, Andrew Breuckner PharmD, Alfred Luk MD, Avinash Aujayeb MBBS MRCP, Daniel Ganger MD, Douglas S. Keith MD, Federica Meloni MD, Ghady Haidar MD, Lori Zapernick, Megan Morales MD, Nitender Goyal MD, Tanvi Sharma MD MPH, Uma Malhotra MD, Alexander Kuo MD, Ana P Rossi MD MPH, Angelina Edwards MD, Brian Keller MD PhD, Christy Beneri DO, Darby Derringer PharmD, Edward Dominguez MD, Elise Carlson PharmD, Faris Hashim MD, Haris Murad MD, Heinrike Wilkens MD, Henry Neumann MD, Imran Gani MD, Joseph Kahwaji MD, Joyce Popoola FRCP, Marian Michaels MD MPH, Niyati Jakharia MD, Oveimar De la Cruz MD, Alfredo Puing MD, Reza Motallebzadeh, Ravi Velagapudi MD, Rajan Kapoor MD, Sridhar Allam MD, Fernanda Silveira MD MD, Surabhi Vora MD MPH, Ursala M Kelly MD, Uttam Reddy MD, Vikas Dharnidharka MD MPH, Hani Wadei MD, and Lominadze Zurabi MD.

Funding: This work was supported by the National Institute of Allergy and Infectious Diseases (T32AI118690 to M.R.H. and O.S.K.) and the National Heart, Lung, and Blood Institute (HL143050 to C.E.F.) at the National Institutes of Health. REDCap at the Institute of Translational Health Sciences at the University of Washington is supported by the National Center for Advancing Translational Sciences of the National Institutes of Health (UL1 TR002319). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Disclosures: M.R.H reports receiving speaking honoraria from Cigna LifeSource and Thermo Fisher Scientific. O.S.K. reports AST PSECOP PILOT Grant outside of the submitted work, received speaking honoraria from the Canadian Society of Transplantation and the American Foundation of Donation and Transplantation, as well as consulting free from Bennett Jones, LLP, outside the scope of this work and AST ID COP Executive Committee. C.N.K. reports grants or contracts from Regeneron, Beigene, and Mendez Foundation; received consulting fees from ExeVir and is a participant in the data safety monitoring board or advisory board of Beigene. B.D.A received consulting fees from Scynexis and served as a site investigator for clinical trials for Scynexis, Cidara, Shire, F2G, Ampylx, Astellas; royalties or licenses from UPTODATE; and IDSA Board of Directors. E.A.B. received research funding from Regeneron for mAb for COVID, Merck letermovir for CMV prophylaxis, Takeda maribavir for CMV treatment, and Hologix for CMV testing, unrelated to the present manuscript, and received Honoraria from the American Society of Nephrology and UpToDate Section Editor (transplant); she serve on the DSMB for Ampylx (BK virus treatment); payment or honoraria from WebMD/Medscape for CMV presentation and ASN for COVID presentation; Am Soc Transplantation Public Policy Chair and Am J Transplantation Deputy Editor. M.H.M. reports NIH T32 Transplant Infectious Diseases Training Grant recipient, funding ended before initiation of this work; served on the scientific review committee for BioNTech for BNT162-17; unpaid leadership or fiduciary role for

LifeGift (local Organ Procurement Organization) Houston, TX, Member of the Medical Advisory Committee. M.G.I received research support, paid to Northwestern University, from GlaxoSmithKline, Pulmocide, and Regeneron; payments made to self for RIV chapters from UpToDate; he is a paid consultant for Adagio, ADMA Biologics, AlloVir, Cidara, Genentech, Roche, Janssen, Shionogi, Takeda, Viracor Eurofins; he is also a paid member of DSMBs from Allovir, CSL Behring, Janssen, Merck, Sequiris, Takeda and Talaris. D.v.D. reports grants from NIH, personal fees from Achaogen, grants and personal fees from Shionogi, personal fees from Allergan, personal fees from Astellas, personal fees from Neumedicine, personal fees from T2biosystems, personal fees from Roche, grants and personal fees from Merck, personal fees from Karius, personal fees from Entasis, personal fees from Wellspring, personal fees from Qpex, personal fees from Pfizer, personal fees from Utility, personal fees from Union, personal fees from British Society for Antimicrobial Chemotherapy, outside the submitted work. J.D.G. has research support from Gilead Sciences, Eli Lilly and Company, Regeneron Pharmaceuticals, NIAID, NIH, BARDA (administered by Merck), and Viracor Eurofins and served as a consultant, speaker or advisory board member for Gilead Sciences and Eli Lilly and Company, and received collaborative services agreements from Labcorp, Monogram Biosciences and Adaptive Biotechnologies. A.W. reports grants or contracts to the institution from NIH, Sanofi, and GSK outside of the submitted work; royalties or licenses from UpToDate; travel reimbursement from Innovative Molecules; provision of vaccine for a clinical trial from Merck; received consulting fees from Aicuris, Crozet, Auritec, Dxnow, and Gilead and is a paid member of DSMBs of Merck, X-Vax and Vir. A.P.L reports grants or contracts from Merck Moderna, Takeda, Allovir, GSK, J&J, and Novartis all outside of the submitted work; reports royalties or licenses from UpToDate; received consulting fees from Merck, GSK, Allovir and Novartis and served on a DSMB for Novartis. V.H. reports grants or contracts with the institution from Merck outside of the submitted work. E.D.L. reports grants or contracts Cystic Fibrosis Foundation LEASE17AB3 outside of the submitted work; chair for OPTN Lung Transplantation Committee and chair for ISHLT Standards and Guidelines Committee. M.M. reports Chair Digital Strategy Advisory Group of IDSA, Councilor,

Transplant Infectious Disease, The Transplantation Society, and Member-at-Large, AST IDCOP Executive Committee. J.M.S. reports American Society of Transplantation/CareDx Fellowship grant – research funding for Hepatitis C in transplant patients and NIH.NIAID T32 grant AI100851 outside of the submitted work and pending patents for gene expression-based classifiers of fungal infection.

Data availability statement: The data that support the findings of this study are available from the corresponding author upon reasonable request.

Accepted Manuscript

References

1. Gupta S, Hayek SS, Wang W, et al. Factors Associated With Death in Critically Ill Patients With Coronavirus Disease 2019 in the US. *JAMA Intern Med* **2020**; 180(11): 1436-47.
2. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* **2020**; 395(10229): 1054-62.
3. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. *JAMA* **2020**.
4. Pereira MR, Mohan S, Cohen DJ, et al. COVID-19 in solid organ transplant recipients: Initial report from the US epicenter. *Am J Transplant* **2020**; 20(7): 1800-8.
5. Buckner FS, McCulloch DJ, Atluri V, et al. Clinical Features and Outcomes of 105 Hospitalized Patients With COVID-19 in Seattle, Washington. *Clin Infect Dis* **2020**; 71(16): 2167-73.
6. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19 - Final Report. *N Engl J Med* **2020**; 383(19): 1813-26.
7. Horby P, Lim WS, Emberson JR, et al. Dexamethasone in Hospitalized Patients with Covid-19. *N Engl J Med* **2021**; 384(8): 693-704.
8. Günster C, Busse R, Spoden M, et al. 6-month mortality and readmissions of hospitalized COVID-19 patients: A nationwide cohort study of 8,679 patients in Germany. *PLoS One* **2021**; 16(8): e0255427.
9. Investigators C-IGobotRNatC-I. Clinical characteristics and day-90 outcomes of 4244 critically ill adults with COVID-19: a prospective cohort study. *Intensive Care Med* **2021**; 47(1): 60-73.
10. Zettersten E, Engerström L, Bell M, et al. Long-term outcome after intensive care for COVID-19: differences between men and women-a nationwide cohort study. *Crit Care* **2021**; 25(1): 86.
11. Peñuelas O, Del Campo-Albendea L, de Aledo ALG, et al. Long-term survival of mechanically ventilated patients with severe COVID-19: an observational cohort study. *Ann Intensive Care* **2021**; 11(1): 143.
12. Kates OS, Haydel BM, Florman SS, et al. COVID-19 in solid organ transplant: A multi-center cohort study. *Clin Infect Dis* **2020**.
13. Coll E, Fernández-Ruiz M, Sánchez-Álvarez JE, et al. COVID-19 in transplant recipients: The Spanish experience. *Am J Transplant* **2020**.
14. Butler CR, Reese PP, Perkins JD, et al. End-of-Life Care among US Adults with ESKD Who Were Waitlisted or Received a Kidney Transplant, 2005-2014. *J Am Soc Nephrol* **2020**; 31(10): 2424-33.
15. Fekkar A, Lampros A, Mayaux J, et al. Occurrence of Invasive Pulmonary Fungal Infections in Patients with Severe COVID-19 Admitted to the ICU. *Am J Respir Crit Care Med* **2021**; 203(3): 307-17.
16. Heldman MR, Kates OS, Safa K, et al. Covid-19 in hospitalized lung and non-lung solid organ transplant recipients: a comparative analysis from a multicenter study. *Am J Transplant* **2021**.

17. Heldman MR, Kates OS, Safa K, et al. Changing Trends in Mortality Among Solid Organ Transplant Recipients Hospitalized for Covid-19 During the Course of the Pandemic. *Am J Transplant* **2021**.
18. Heldman MR, Kates OS, Haydel BM, et al. Healthcare resource use among solid organ transplant recipients hospitalized with COVID-19. *Clin Transplant* **2020**: e14174.
19. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. *J Biomed Inform* **2009**; 42(2): 377-81.
20. Finelli L, Gupta V, Petigara T, Yu K, Bauer KA, Puzniak LA. Mortality Among US Patients Hospitalized With SARS-CoV-2 Infection in 2020. *JAMA Netw Open* **2021**; 4(4): e216556.
21. Nguyen NT, Chinn J, Nahmias J, et al. Outcomes and Mortality Among Adults Hospitalized With COVID-19 at US Medical Centers. *JAMA Netw Open* **2021**; 4(3): e210417.
22. Matta A, Chaudhary S, Bryan Lo K, et al. Timing of Intubation and Its Implications on Outcomes in Critically Ill Patients With Coronavirus Disease 2019 Infection. *Crit Care Explor* **2020**; 2(10): e0262.
23. Royston P. Multiple imputation of missing values. *Stata Journal* **2004**; 4(3): 227-41.
24. Quante M, Brake L, Tolios A, et al. SARS-CoV-2 in Solid Organ Transplant Recipients: A Structured Review of 2020. *Transplant Proc* **2021**.
25. Requião-Moura LR, Sandes-Freitas TV, Viana LA, et al. High mortality among kidney transplant recipients diagnosed with coronavirus disease 2019: Results from the Brazilian multicenter cohort study. *PLoS One* **2021**; 16(7): e0254822.
26. Hadi YB, Naqvi SF, Kupec JT, Sofka S, Sarwari A. Outcomes of Coronavirus Infectious Disease -19 (COVID-19) in Solid Organ Transplant Recipients: A Propensity Matched Analysis of a Large Research Network. *Transplantation* **2021**.
27. Marconi VC, Ramanan AV, de Bono S, et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. *Lancet Respir Med* **2021**.
28. Cates J, Lucero-Obusan C, Dahl RM, et al. Risk for In-Hospital Complications Associated with COVID-19 and Influenza - Veterans Health Administration, United States, October 1, 2018-May 31, 2020. *MMWR Morb Mortal Wkly Rep* **2020**; 69(42): 1528-34.
29. Shukla BS, Warde PR, Knott E, et al. Bloodstream Infection Risk, Incidence, and Deaths for Hospitalized Patients during Coronavirus Disease Pandemic. *Emerg Infect Dis* **2021**; 27(10): 2588-94.
30. Courtwright AM, Erler KS, Bandini JJ, et al. Ethics Consultation for Adult Solid Organ Transplantation Candidates and Recipients: A Single Centre Experience. *J Bioeth Inq* **2021**; 18(2): 291-303.
31. Courtwright AM, Rubin E, Robinson EM, et al. An Ethical Framework for the Care of Patients with Prolonged Hospitalization Following Lung Transplantation. *HEC Forum* **2019**; 31(1): 49-62.
32. Maxwell BG, Levitt JE, Goldstein BA, et al. Impact of the lung allocation score on survival beyond 1 year. *Am J Transplant* **2014**; 14(10): 2288-94.

33. Zheng Y, Li R, Liu S. Immunoregulation with mTOR inhibitors to prevent COVID-19 severity: A novel intervention strategy beyond vaccines and specific antiviral medicines. *Journal of medical virology* **2020**; 92(9): 1495-500.
34. Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N Engl J Med* **2020**.
35. Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *N Engl J Med* **2020**.
36. Sadoff J, Gray G, Vandebosch A, et al. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. *N Engl J Med* **2021**; 384(23): 2187-201.
37. Ravanan R, Mumford L, Ushiro-Lumb I, et al. Two Doses of SARS-CoV-2 Vaccines Reduce Risk of Death Due to COVID-19 in Solid Organ Transplant Recipients: Preliminary Outcomes From a UK Registry Linkage Analysis. *Transplantation* **2021**.
38. Anjan S, Natori Y, Fernandez Betances AA, et al. Breakthrough COVID-19 Infections After mRNA Vaccination in Solid Organ Transplant Recipients in Miami, Florida. *Transplantation* **2021**; 105(10): e139-e41.
39. Walensky RP, Walke HT, Fauci AS. SARS-CoV-2 Variants of Concern in the United States-Challenges and Opportunities. *JAMA* **2021**; 325(11): 1037-8.

Accepted Manuscript

Table 1: Characteristics of solid organ transplant recipients hospitalized for COVID-19^a

Characteristic, n (%)	Followed through day 28 (n=1117)	Followed through day 90 (n=936)
Men	694 (62.2)	581 (62.1)
Age > 65 years	343 (30.7)	290 (31.0)
Median age, years (IQR)	59 (49-67)	60 (49-67)
Black race	370 (34.8)	287 (32.0)
Hispanic or Latinx ethnicity	338 (31.3)	298 (33.0)
Transplant within 2 years	368 (33.8)	323 (35.4)
Organ^b		
Kidney	693 (62.0)	567 (60.6)
Liver	157 (14.1)	134 (14.3)
Heart	137 (12.3)	114 (12.2)
Lung	127 (11.4)	119 (12.7)
Other	3 (0.3)	2 (0.21)
Comorbidities		
Diabetes mellitus	563 (50.4)	475 (50.8)
BMI \geq 30 kg/m ²	382 (35.8)	318 (35.7)
CKD or ESRD	406 (36.4)	325 (35.7)
Heart failure	69 (6.2)	57 (6.1)
Chronic lung disease	74 (6.6)	61 (6.5)
Baseline immunosuppression		
Any CNI	1024 (91.7)	850 (90.8)
Any anti-metabolite	836 (74.8)	709 (75.8)
Any corticosteroid	818 (73.2)	682 (72.9)
CNI, anti-metabolite, steroids	589 (52.7)	498 (53.2)
Any mTOR inhibitor	65 (5.8)	54 (5.8)
Recent intensive immunosuppression	67 (6.0)	63 (6.8)
Time period of diagnosis		
Early 2020 (before June 20, 2020)	593 (53.1)	458 (48.9)
Late 2020 (on or after June 20, 2020)	411 (36.8)	371 (39.6)
Unknown	113 (10.1)	107 (11.4)
Surrogate markers of illness severity at presentation		
Abnormal chest imaging ^d	835 (82.3)	689 (81.9)
Lymphopenia (ALC $<0.5 \times 10^9/L$)	325 (31.5)	275 (32.3)

Abbreviations: absolute lymphocyte count (ALC), body mass index (BMI), calcineurin inhibitor (CNI), chronic kidney disease (CKD), end stage renal disease (ESRD), mammalian target of rapamycin (mTOR)

^a Among the 1117 patients followed through day 28: Sex missing for one patient; race was missing for 54 patients; ethnicity was missing for 38 patients; year of most recent transplant was missing for 28 patients; BMI was missing for 50 patients; chest imaging was not performed for 102 patients. Presenting absolute lymphocyte count was missing for 85 patients.

Among the 936 patients followed through day 90: Sex was missing for one patient; race was missing for 38 patients; ethnicity was missing for 27 patients; year of most recent transplant was missing for 22 patients; BMI was missing for 46 patients; time period of diagnosis was missing for 107 patients; chest imaging was missing or not performed for 95 patients; absolute lymphocyte count at presentation was missing for 80 patients. Patient race and ethnicity were collected as distinct variables and reported by the contributor based on observations or documentation in the electronic medical record. Race and ethnicity were collected as part of the registry to characterize the study population.

^b Among the 1117 patients followed through day 28: Kidney includes 19 kidney-pancreas recipients; Liver includes 34 liver/kidney recipients, 1 liver/pancreas/small bowel recipient and 1 liver/kidney/small bowel/stomach recipient; Heart includes 15 heart/kidney recipients and 1 heart/kidney/small-bowel recipient; Lung includes 3 heart/lung, 1 lung/liver recipients, 1 lung/kidney/small bowel recipient; Other includes 2 small bowel and 1 vascular composite allograft recipients.

Among the 926 patients followed through day 90: Kidney includes 15 kidney/pancreas recipients; liver includes 23 liver/kidney recipients, 1 liver/pancreas/small bowel recipient and 1 liver/pancreas/small bowel/stomach recipient; heart includes 14 heart/kidney recipients and 1 heart/kidney/small bowel recipient; lung includes 2 heart/lung recipients, 1 lung/liver recipient and 1 lung/kidney/islet cell recipient.

^c Recent intensive immunosuppression refers to agents with significant T cell, B cell or immunoglobulin depleting activity given within the 3 months prior to SARS-CoV-2 diagnosis. For the 1117 patients followed through day 28, agents included anti-thymocyte globulin (n=37), alemtuzumab (n=2), basiliximab (n=17), pulse steroids, defined as equivalent of ≥ 500 mg methylprednisolone for ≥ 3 days (n=24), rituximab (n=4), plasmapheresis (n=1), bortezomib (n=1).

Among the 936 patients followed through day 90, agents included: anti-thymocyte globulin (n=34), alemtuzumab (n=2), basiliximab (n=17), pulse steroids, defined as equivalent of ≥ 500 mg methylprednisolone for ≥ 3 days (n=21), rituximab (n=4), plasmapheresis (n=1), bortezomib (n=1).

^d Abnormal chest imaging findings on x-ray or computed tomography included lobar consolidation, multifocal or patchy opacities, including ground glass, interstitial abnormalities, or other findings deemed clinically significant by the contributing provider.

Table 2: Mortality by 90 days following first positive SARS-CoV-2 test in solid organ transplant recipients hospitalized for COVID-19

	Patients with known status vital status at day 90 (n=936)	Entire cohort, (n=1117)
Day 0-28	190 (20.3%)	190 (17.0%)
Day 29-90	56 (6.0%)	56-237 (5.0-21.2%) *
Overall mortality (Day 0-90)	246 (26.3%)	246-427 (22.0-38.0%) *

*Range includes the minimum and maximum possible value for mortality in the entire cohort. In sensitivity analysis, minimum mortality estimate assumes 0% mortality among patients lost to follow-up and the maximum mortality assumes 100% mortality among patients lost to follow-up.

Accepted Manuscript

Table 3: Risk factors for mortality by day 28 and day 90 in solid organ transplant recipients hospitalized for COVID-19, univariable Cox-proportional hazards (N=1117)

Covariate	Mortality by day 28	Mortality by day 90
	Hazard Ratio (95% Confidence Interval), p-value	
Men	1.0 (0.76-1.4), 0.91	1.2 (0.9-1.6), 0.12
Age > 65 years	2.1 (1.6-2.7), <0.001	2.0 (1.6-2.6), <0.001
Transplant within 2 years	0.76 (0.55-1.0), 0.09	1.0 (0.7-1.3), 0.81
Lung Transplant (vs. non-lung)	1.5 (1.0-2.2), 0.047	1.4 (1.0-1.9), 0.10
Comorbidities		
Hypertension	1.3 (0.9-1.9), 0.14	1.4 (1.0-1.9), 0.04
Diabetes mellitus	1.6 (1.2-2.2), 0.01	1.6 (1.3-2.1), <0.001
BMI \geq 30 kg/m ²	1.5 (1.1-2.0), 0.01	1.3 (1.0-1.7), 0.06
CKD/ESRD	1.3 (0.98-1.8), 0.06	1.2 (0.9-1.5), 0.24
Heart failure	2.8 (1.8-4.2), <0.001	2.5 (1.7-3.6), <0.001
Chronic lung disease	3.4 (2.3-4.9), <0.001	2.9 (2.0-4.2), <0.001
Baseline immunosuppression		
Any CNI	1.1 (0.6-1.8), 0.76	1.0 (0.65-1.6), 0.96
Any anti-metabolite	0.87(0.6-1.2), 0.40	0.9 (0.7-1.2), 0.56
Any corticosteroid	1.1 (0.8-1.5), 0.58	1.1 (0.8-1.4), 0.64
CNI, ant-metabolite, steroids	0.98 (0.7-1.3), 0.87	1.0 (0.8-1.2), 0.75
Any mTOR inhibitor	0.3 (0.1-0.9), 0.03	0.4 (0.2-0.9), 0.03
Recent intensive immunosuppression	0.5 (0.2-1.1), 0.09	0.9 (0.5-1.5), 0.65
Time period of diagnosis		
Late 2020 (on or after June 20, 2020)	0.7 (0.5-0.9), 0.01	0.9 (0.7-1.1), 0.29
Markers of illness severity at presentation		
Abnormal chest imaging	3.5 (1.9-6.4), <0.001	3.4 (2.0-5.8), <0.001
Lymphopenia (ALC <0.5 x	1.8 (1.3-2.4), <0.001	1.8 (1.4-2.4), <0.001

Abbreviations: absolute lymphocyte count (ALC), body mass index (BMI), chronic kidney disease (CKD), calcineurin inhibitor (CNI), end stage renal disease (ESRD), mammalian target of rapamycin (mTOR)

Statistically significant values ($p \leq 0.05$) are shown in **bold**.

Table 4: Risk factors for mortality by day 28 and day 90 in solid organ transplant recipients hospitalized for COVID-19, multivariable Cox proportional hazards (N=1117)

Covariate	Mortality by 28 days	Mortality by 90 days
	Adjusted Hazard Ratio (95% Confidence Interval), p-	
Age >65 years	1.8 (1.3-2.6), <0.001	1.8 (1.3-2.4), <0.001
Lung transplant (vs. non-lung)	1.8 (1.1-2.8), 0.02	1.5 (1.0-2.3), 0.05
Comorbidities ^a		
Diabetes mellitus	1.2 (0.8-1.7), 0.34	1.3 (1.0-1.8), 0.09
Heart failure	1.9 (1.2-3.1), 0.01	1.9 (1.2-2.9), 0.006
Chronic lung disease	2.4 (1.5-3.7), <0.001	2.3 (1.5-3.6), <0.001
BMI \geq 30 kg/m ²	1.6 (1.1-2.2), 0.01	1.5 (1.1-2.0), 0.02
Baseline mTOR inhibitor use	0.3 (0.1-1.0), 0.05	0.5 (0.2-1.1), 0.07
Late 2020 (on or after June 20, 2020)	0.7 (0.5-1.0), 0.04	0.9 (0.7-1.3), 0.61
Lymphopenia (ALC <0.5 x 10 ⁹ /L) at presentation	1.8 (1.3-2.6), <0.001	1.8 (1.3-2.4), <0.001
Abnormal chest imaging at presentation	2.9 (1.5-5.5), 0.002	2.7 (1.6-4.7), <0.001

Abbreviations: absolute lymphocyte count (ALC), body mass index (BMI), mammalian target of rapamycin (mTOR)

Statistically significant values (p \leq 0.05) are shown in **bold**.

Figure Titles and Captions

Figure 1 Unadjusted Kaplan-Meier survival curves in solid organ transplant recipients hospitalized for COVID-19

Figure 1 Caption : Unadjusted Kaplan-Meier survival curves for hospitalized solid organ transplant recipients (A) and stratified by organ (B), and time period of diagnosis: early 2020 (before June 20, 2020) and late 2020 (on or after June 20, 2020) (C). Grey shading represents 95% confidence intervals. Vertical marks represent patients censored at time of last live encounter.

Figure 2 Title : Proportion of deaths before and after day 28 in solid organ transplant recipients hospitalized for COVID-19

Figure 2 Caption: Covariates of interest (total number deaths between days 0-90) and proportion of deaths that occurred between days 0-28 (gray) and days 29-90 (black) in solid organ transplant recipients hospitalized for COVID-19.

Accepted Manuscript

Figure 1





Figure 2



Accept